Psych Congress NetworkLumateperone Tops Efficacy in Adjunctive Treatment for MDD, Review Finds

A JAMA Psychiatry network meta-analysis of 22 short-term trials and 10,962 patients compared five FDA-approved atypical antipsychotics used adjunctively for MDD with inadequate antidepressant response. The synthesis surfaced clinically meaningful differences in efficacy and discontinuation across agents.

Clinical Considerations

• Lumateperone showed the largest efficacy signal (RR 1.72) but the lowest acceptability (RR 2.30 for all-cause discontinuation).
• Aripiprazole ranked second for efficacy (RR 1.53) and highest for acceptability, suggesting a favorable balance for sustained use.
• Brexpiprazole and cariprazine showed intermediate efficacy with comparatively favorable tolerability profiles.
• Authors flagged a maintenance evidence gap, with no adequately powered long-term trials evaluating sustained benefit of adjunctive atypical antipsychotics in MDD.

Practice Applications

• Consider efficacy-tolerability tradeoffs when selecting adjunctive agents for treatment-resistant depression.
• Recognize lumateperone’s strong short-term efficacy alongside its higher discontinuation rate.
• Monitor weight, metabolic parameters, and tolerability across prolonged treatment courses.
• Interpret rankings as short-term comparative data, not maintenance-phase guidance.